A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: immunity therapy
- Registration Number
- NCT04777175
- Lead Sponsor
- Yongchang Zhang
- Brief Summary
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 186
Inclusion Criteria
- 1.Diagnosed as advanced non-small cell lung cancer
- 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation
Exclusion Criteria
- The patient is diagnosed with small cell lung cancer
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description KRAS mutation immunity therapy patients carry with KRAS mutation ALK fusion immunity therapy patients carry with ALK fusion ERBB2 mutation immunity therapy patients carry with ERBB2 mutation MET skipping/amplication immunity therapy patients carry with MET skipping/amplication RET fusion immunity therapy patients carry with RET fusion BRAF mutation immunity therapy patients carry with BRAF mutation
- Primary Outcome Measures
Name Time Method PFS January 2021- January 2021 (1 year) Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Hunan Cancer Hospital
🇨🇳Changsha, Hunan, China
Hunan Cancer hospital
🇨🇳Changsha, Hunan, China